/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

LUCID DIAGNOSTICS INC. Share Price Today: Live Updates & Key Insights

LUCID DIAGNOSTICS INC. share price today is $1.43, up -4.14%. The stock opened at $1.42 against the previous close of $1.45, with an intraday high of $1.425 and low of $1.365.

LUCID DIAGNOSTICS INC. Share Price Chart

style
pb-0

LUCID DIAGNOSTICS INC.

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0

LUCID DIAGNOSTICS INC. Share Price Performance

$1.43 -0.0414(-4.14%) LUCD at 13 Mar 2026 02:10 PM Medical Devices
Lowest Today 1.365
Highest Today 1.425
Today’s Open 1.42
Prev. Close 1.45
52 Week High 1.80
52 Week Low 0.95
Day’s Range: Low 1.365 High 1.425
52-Week Range: Low 0.95 High 1.80
1 day return -
1 Week return -0.35
1 month return +6.06
3 month return +25.56
6 month return +32.07
1 year return +9.37
3 year return -13.04
5 year return -88.5
10 year return -

LUCID DIAGNOSTICS INC. Institutional Holdings

Vanguard Group Inc 3.79

Masters Capital Management LLC 3.05

BlackRock Inc 2.80

Aberdeen Group PLC 2.64

abrdn Healthcare Opportunities 2.64

Vanguard Total Stock Mkt Idx Inv 2.31

Two Seas Capital LP 2.29

Ghisallo Capital Management LLC 2.26

iShares Russell 2000 ETF 1.66

Geode Capital Management, LLC 1.28

Perkins Capital Management Inc 0.86

Vanguard Institutional Extnd Mkt Idx Tr 0.84

State Street Corp 0.78

Fidelity Small Cap Index 0.66

Renaissance Technologies Corp 0.63

Wells Fargo & Co 0.54

The Goldman Sachs Group Inc 0.43

Northern Trust Corp 0.38

Fidelity Extended Market Index 0.38

iShares Russell 2000 Value ETF 0.33

Vanguard Russell 2000 ETF 0.33

State St Russell Sm/Mid Cp® Indx SL Cl I 0.30

Sunbelt Securities 0.29

Lido Advisors, LLC 0.29

Luminus Management, LLC 0.28

iShares Russell 2000 Growth ETF 0.28

Squarepoint Ops LLC 0.26

First Manhattan Co. LLC 0.25

State St Russell Sm Cap® Indx SL Cl I 0.18

iShares Micro-Cap ETF 0.18

Charles Schwab Investment Management Inc 0.17

Schwab Small Cap Index 0.17

NT R2000 Index Fund - NL 0.16

Bank of New York Mellon Corp 0.16

Blackrock Extended Mkt Fund CF 0.14

Fidelity Total Market Index 0.13

NT R2000 Index Fund - DC - NL - 3 0.13

Extended Equity Market Fund K 0.12

Fidelity Series Total Market Index 0.09

iShares Russell 2000 Small-Cap Idx Instl 0.09

LUCID DIAGNOSTICS INC. Market Status

Strong Buy: 4

Buy: 2

Hold: 0

Sell: 0

Strong Sell: 0

LUCID DIAGNOSTICS INC. Fundamentals

Market Cap 190.09 M

PB Ratio 2.159

PE Ratio 0.0

Enterprise Value 221.37 M

Total Assets 30.72 M

Volume 466798

LUCID DIAGNOSTICS INC. Company Financials

Annual Revenue FY23:1500000 1.5M, FY22:377000 0.4M, FY21:500000 0.5M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:-4640000 -4.6M, FY22:-3237000 -3.2M, FY21:-85000 -0.1M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-56764000 -56.8M, FY22:-56171000 -56.2M, FY21:-28737000 -28.7M, FY20:-8279517 -8.3M, FY19:-4420544 -4.4M

Quarterly Revenue Q3/2025:1211000 1.2M, Q2/2025:1163000 1.2M, Q1/2025:828000 0.8M, Q3/2024:1172000 1.2M, Q2/2024:976000 1.0M

Quarterly Profit Q3/2025:-706000 -0.7M, Q2/2025:-622000 -0.6M, Q1/2025:-723000 -0.7M, Q3/2024:-512000 -0.5M, Q2/2024:-867000 -0.9M

Quarterly Net worth Q3/2025:-10397000 -10.4M, Q2/2025:-4439000 -4.4M, Q1/2025:-26908000 -26.9M, Q3/2024:-12371000 -12.4M, Q2/2024:-11005000 -11.0M

About LUCID DIAGNOSTICS INC. & investment objective

Company Information Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. operates as a subsidiary of PAVmed Inc.

Organisation Medical Devices

Employees 72

Industry Medical Devices

CEO Dr. Lishan Aklog M.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow